Replies to post #350121 on Innovation Pharmaceuticals Inc (IPIX)

[Jhawker]

After reading that it doesn’t look that successful.

[sunspotter]

Pretty impressive results for a Phase II study with mortality as part of its primary endpoints.

Among several things worth noting is the fact that remdesivir was only given to just over 65% of patients as Standard of Care whereas dexamethasone or other steroids were given to over 90%:

"CERC-002 showed statistically significant efficacy on top of corticosteroids and standard of care treatments in COVID-19 ARDS: over 90% of patients received concomitant systemic corticosteroids and over 65% received remdesivir."


https://ir.cerecor.com/press-releases/detail/121/cerecor-announces-cerc-002-significantly-reduced

This confirms my earlier posts stating that remdesivir is not going to be used in every patient in the brilacidin study contrary to bold but false assertions in other posts.